PLX - Margin resik Protalix

Simbol lan logo merek Protalix BioTherapeutics Inc. (PLX)

Protalix BioTherapeutics revenues are based on a single Fabry disease treatment, the distribution of which is guaranteed by a global partner. The net margin reflects the dynamics of this dependency, where the value 24.30 represents the current figure. FDA-certified Israeli plants ensure business efficiency. The company's advantage is the ProCellEx platform, which produces low-cost therapeutic proteins in plant cells.

Protalix BioTherapeutics (PLX) - Margin dodolan resik saka 04.07.2022 nganti 19.11.2026

Protalix BioTherapeutics, Inc (PLX) - rincian metrik lan laporan keuangan

Analisis komprehensif perusahaan:Protalix BioTherapeutics, PLX
Produk asil prodhuksi Protalix

The efficiency of Protalix BioTherapeutics (PLX) depends directly on the commercialization of its Fabry disease drug and the receipt of royalties, making the control of operating expenses critical. Current net profit margin measures the portion of profit in every dollar of revenue, allowing investors to assess the business model's resilience to costs associated with expanding insurance coverage and determine the asset's real margin of safety.